Watch Ticker

Context Therapeutics Inc. Common Stock

Go to Context Therapeutics Inc. Common Stock Website

$0.69

0.01 (0.88%)

Live

Previous Close

$0.7

Day Range

$0.6801 - $0.7149

Previous Day Range

$0.6752 - $0.728

Market Cap

$61.0 million USD

Day Vol.

104124

Previous Day Vol.

184951

Currency

USD

Primary Exchange

Nasdaq

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, includin...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Context Therapeutics Inc. - Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Context Therapeutics Inc. announced the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody, for CLDN6-positive gynecologic and testicular cancers. The company expects to share initial data in the first half of 2026.

Related tickers: CNTX.

Read Full Article

Prnewswire - Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

The oncology field is advancing with emerging immunotherapies and AI-driven personalized cell therapies. Key players like Oncolytics Biotech, Erasca, Allogene Therapeutics, Context Therapeutics, and Recursion Pharmaceuticals are driving progress in areas like breast, GI, and renal cell cancers.

Related tickers: ONCY, ERAS, ALLO, CNTX, RXRX.

Read Full Article

Trending Tickers

Please sign in to view